-

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time):

  • The 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 12:00 p.m.
  • The Nasdaq 51st Investor Conference in London on Tuesday, December 10, 2024 at 5:30 a.m.
  • The J.P. Morgan 43rd Annual Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 6:45 p.m.

To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will also be available following the events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners.

Contacts

Investor Relations:
Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

Industry:

Insulet Corporation

NASDAQ:PODD
Release Versions
English

Contacts

Investor Relations:
Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

More News From Insulet Corporation

Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation:...

Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced the expansion of its U.S. Pod recycling program, which is now available to all U.S. customers. “Here at Insulet, our mission is to transform the lives of people with diabetes, and we are equally committed to creating a more sustainable future,” said Carolyn Sleeth, Senior Vice President and U.S. Ge...

Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new benchmark in tubeless diabetes technology by offering a lower 100 mg/dL Target Glucose option and a more seamless automated experie...
Back to Newsroom